Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Roquefort Investments PLC ( (GB:ROQ) ) has provided an update.
Roquefort Therapeutics PLC announced that Dr. Simon Sinclair, a Non-Executive Director, has acquired 72,507 ordinary shares of the company at an average price of 1.37 pence per share, increasing his total shareholding to 108,428 shares, which represents 0.07% of the company’s issued capital. This transaction reflects confidence in the company’s strategic direction and potential growth in the high-value immunology and oncology markets.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, specializing in developing first-in-class drugs for the immunology and oncology markets. The company focuses on creating high-value, high-growth medicines and holds a portfolio of five novel, patent-protected pre-clinical anti-cancer and immunology assets.
Average Trading Volume: 1,111,043
Technical Sentiment Signal: Sell
Current Market Cap: £1.97M
Find detailed analytics on ROQ stock on TipRanks’ Stock Analysis page.